Skip to main content
Top
Published in: Journal of Bone and Mineral Metabolism 3/2017

01-05-2017 | Original Article

Reports of 17 Chinese patients with tumor-induced osteomalacia

Authors: Wei-Jia Yu, Jin-Wei He, Wen-Zhen Fu, Chun Wang, Zhen-Lin Zhang

Published in: Journal of Bone and Mineral Metabolism | Issue 3/2017

Login to get access

Abstract

Tumor-induced osteomalacia (TIO) is a rare acquired form of hypophosphatemic osteomalacia, which is usually attributed to the overproduction of fibroblast growth factor 23 (FGF-23) by benign mesenchymal neoplasms. Localization and thereafter surgical resection of tumors lead to a cure. The present study aimed to investigate the clinical data, diagnostic methods, and follow-up after tumor resection at one medical center in Shanghai to characterize the profile of this rare disorder and to share our successful experience in diagnosis and treatment. Twenty-three patients with adult-onset hypophosphatemia osteomalacia seen in Shanghai Sixth People’s Hospital from 2009 to 2014 and 95 normal individuals were enrolled. After taking a medical history and performing a physical examination, we analyzed the laboratory results (including the serum FGF-23 levels) and localized the tumors by 18F-fluorodeoxyglucose positron emission tomography and computed tomography (18F-FDG PET/CT), 99mTc-octreotide (99mTc-OCT) scintigraphy, and magnetic resonance imaging (MRI). On the basis of the results of laboratory tests and imaging findings, tumor resection was conducted in 17 patients with a certain diagnosis of TIO. The results demonstrated that the 17 patients (nine men and eight women, average age 46.6 ± 12.9 years) had TIO. FGF-23 level was elevated in 94.1 % of patients (16 of 17 patients) . Serum phosphorus level decreased in 100 % of patients. 18F-FDG PET/CT revealed five tumors, 99mTc-OCT scintigraphy revealed two tumors, physical examination revealed nine tumors, and MRI revealed one tumor, among which 58.8 % of the causative tumors (10 of 17 tumors) were located in the lower extremities. After tumor resection, serum phosphorus levels normalized in 100 % of patients (all 17 patients) in 4–21 days and FGF-23 levels decreased in 90 % of patients (nine of ten patients). We found 64.7 % of the tumors (11 of 17 tumors) were phosphaturic mesenchymal tumors or a phosphaturic mesenchymal tumor mixed connective tissue variant. Measurement of serum phosphorus and FGF-23 levels in patients with suspected TIO is of paramount importance for diagnosing of TIO. 18F-FDG PET/CT, 99mTc-OCT scintigraphy, and physical examination play a considerable role in revealing TIO-associated tumors. TIO-associated tumors were more frequently located in the lower extremities than in other places; thus, the lower extremities need to be carefully checked. Complete surgical resection results in normalization of parameters in laboratory tests and relief of symptoms of TIO patients.
Literature
1.
go back to reference Prader A, Illig R, Uehlinger E, Stalder G (1959) Rickets following bone tumor. Helv Paediatr Acta 14:554–565PubMed Prader A, Illig R, Uehlinger E, Stalder G (1959) Rickets following bone tumor. Helv Paediatr Acta 14:554–565PubMed
2.
go back to reference Jiang Y, Xia WB, Xing XP, Silva BC, Li M, Wang O, Zhang HB, Li F, Jing HL, Zhong DR, Jin J, Gao P, Zhou L, Qi F, Yu W, Bilezikian JP, Meng XW (2012) Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: report of 39 cases and review of the literature. J Bone Miner Res 27:1967–1975CrossRefPubMed Jiang Y, Xia WB, Xing XP, Silva BC, Li M, Wang O, Zhang HB, Li F, Jing HL, Zhong DR, Jin J, Gao P, Zhou L, Qi F, Yu W, Bilezikian JP, Meng XW (2012) Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: report of 39 cases and review of the literature. J Bone Miner Res 27:1967–1975CrossRefPubMed
4.
go back to reference Jadhav S, Kasaliwal R, Lele V, Rangarajan V, Chandra P, Shah H, Malhotra G, Jagtap VS, Budyal S, Lila AR, Bandgar T, Shah NS (2014) Functional imaging in primary tumour-induced osteomalacia: relative performance of FDG PET/CT vs somatostatin receptor-based functional scans: a series of nine patients. Clin Endocrinol (Oxf) 81:31–37CrossRef Jadhav S, Kasaliwal R, Lele V, Rangarajan V, Chandra P, Shah H, Malhotra G, Jagtap VS, Budyal S, Lila AR, Bandgar T, Shah NS (2014) Functional imaging in primary tumour-induced osteomalacia: relative performance of FDG PET/CT vs somatostatin receptor-based functional scans: a series of nine patients. Clin Endocrinol (Oxf) 81:31–37CrossRef
5.
go back to reference Chong WH, Andreopoulou P, Chen CC, Reynolds J, Guthrie L, Kelly M, Gafni RI, Bhattacharyya N, Boyce AM, El-Maouche D, Crespo DO, Sherry R, Chang R, Wodajo FM, Kletter GB, Dwyer A, Collins MT (2013) Tumor localization and biochemical response to cure in tumor-induced osteomalacia. J Bone Miner Res 28:1386–1398CrossRefPubMedPubMedCentral Chong WH, Andreopoulou P, Chen CC, Reynolds J, Guthrie L, Kelly M, Gafni RI, Bhattacharyya N, Boyce AM, El-Maouche D, Crespo DO, Sherry R, Chang R, Wodajo FM, Kletter GB, Dwyer A, Collins MT (2013) Tumor localization and biochemical response to cure in tumor-induced osteomalacia. J Bone Miner Res 28:1386–1398CrossRefPubMedPubMedCentral
6.
go back to reference Econs MJ, Drezner MK (1994) Tumor-induced osteomalacia—unveiling a new hormone. N Engl J Med 330:1679–1681CrossRefPubMed Econs MJ, Drezner MK (1994) Tumor-induced osteomalacia—unveiling a new hormone. N Engl J Med 330:1679–1681CrossRefPubMed
8.
go back to reference Fukumoto S, Takeuchi Y, Nagano A, Fujita T (1999) Diagnostic utility of magnetic resonance imaging skeletal survey in a patient with oncogenic osteomalacia. Bone 25:375–377CrossRefPubMed Fukumoto S, Takeuchi Y, Nagano A, Fujita T (1999) Diagnostic utility of magnetic resonance imaging skeletal survey in a patient with oncogenic osteomalacia. Bone 25:375–377CrossRefPubMed
9.
go back to reference Dupond JL, Mahammedi H, Prie D, Collin F, Gil H, Blagosklonov O, Ricbourg B, Meaux-Ruault N, Kantelip B (2005) Oncogenic osteomalacia: diagnostic importance of fibroblast growth factor 23 and F-18 fluorodeoxyglucose PET/CT scan for the diagnosis and follow-up in one case. Bone 36:375–378CrossRefPubMed Dupond JL, Mahammedi H, Prie D, Collin F, Gil H, Blagosklonov O, Ricbourg B, Meaux-Ruault N, Kantelip B (2005) Oncogenic osteomalacia: diagnostic importance of fibroblast growth factor 23 and F-18 fluorodeoxyglucose PET/CT scan for the diagnosis and follow-up in one case. Bone 36:375–378CrossRefPubMed
10.
go back to reference Hodgson SF, Clarke BL, Tebben PJ, Mullan BP, Cooney WP 3rd, Shives TC (2006) Oncogenic osteomalacia: localization of underlying peripheral mesenchymal tumors with use of Tc 99m sestamibi scintigraphy. Endocr Pract 12:35–42CrossRefPubMed Hodgson SF, Clarke BL, Tebben PJ, Mullan BP, Cooney WP 3rd, Shives TC (2006) Oncogenic osteomalacia: localization of underlying peripheral mesenchymal tumors with use of Tc 99m sestamibi scintigraphy. Endocr Pract 12:35–42CrossRefPubMed
11.
go back to reference Jan de Beur SM, Streeten EA, Civelek AC, McCarthy EF, Uribe L, Marx SJ, Onobrakpeya O, Raisz LG, Watts NB, Sharon M, Levine MA (2002) Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet 359:761–763CrossRefPubMed Jan de Beur SM, Streeten EA, Civelek AC, McCarthy EF, Uribe L, Marx SJ, Onobrakpeya O, Raisz LG, Watts NB, Sharon M, Levine MA (2002) Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet 359:761–763CrossRefPubMed
12.
go back to reference Walton RJ, Bijvoet OL (1975) Nomogram for derivation of renal threshold phosphate concentration. Lancet 2:309–310CrossRefPubMed Walton RJ, Bijvoet OL (1975) Nomogram for derivation of renal threshold phosphate concentration. Lancet 2:309–310CrossRefPubMed
13.
go back to reference Qiu ZL, Xue YL, Song HJ, Luo QY (2012) Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer. Nucl Med Commun 33:1232–1242CrossRefPubMed Qiu ZL, Xue YL, Song HJ, Luo QY (2012) Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer. Nucl Med Commun 33:1232–1242CrossRefPubMed
14.
go back to reference White KE, Jonsson KB, Carn G, Hampson G, Spector TD, Mannstadt M, Lorenz-Depiereux B, Miyauchi A, Yang IM, Ljunggren O, Meitinger T, Strom TM, Juppner H, Econs MJ (2001) The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab 86:497–500CrossRefPubMed White KE, Jonsson KB, Carn G, Hampson G, Spector TD, Mannstadt M, Lorenz-Depiereux B, Miyauchi A, Yang IM, Ljunggren O, Meitinger T, Strom TM, Juppner H, Econs MJ (2001) The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab 86:497–500CrossRefPubMed
15.
go back to reference White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ (2001) Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60:2079–2086CrossRefPubMed White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ (2001) Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60:2079–2086CrossRefPubMed
16.
go back to reference Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T (2001) Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 98:6500–6505CrossRefPubMedPubMedCentral Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T (2001) Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 98:6500–6505CrossRefPubMedPubMedCentral
17.
go back to reference Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:429–435CrossRefPubMed Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:429–435CrossRefPubMed
18.
go back to reference Tenenhouse HS, Sabbagh Y (2002) Novel phosphate-regulating genes in the pathogenesis of renal phosphate wasting disorders. Pflugers Arch 444:317–326CrossRefPubMed Tenenhouse HS, Sabbagh Y (2002) Novel phosphate-regulating genes in the pathogenesis of renal phosphate wasting disorders. Pflugers Arch 444:317–326CrossRefPubMed
19.
go back to reference Nelson AE, Bligh RC, Mirams M, Gill A, Au A, Clarkson A, Juppner H, Ruff S, Stalley P, Scolyer RA, Robinson BG, Mason RS, Bligh PC (2003) Clinical case seminar: fibroblast growth factor 23: a new clinical marker for oncogenic osteomalacia. J Clin Endocrinol Metab 88:4088–4094CrossRefPubMed Nelson AE, Bligh RC, Mirams M, Gill A, Au A, Clarkson A, Juppner H, Ruff S, Stalley P, Scolyer RA, Robinson BG, Mason RS, Bligh PC (2003) Clinical case seminar: fibroblast growth factor 23: a new clinical marker for oncogenic osteomalacia. J Clin Endocrinol Metab 88:4088–4094CrossRefPubMed
20.
go back to reference Jagtap VS, Sarathi V, Lila AR, Malhotra G, Sankhe SS, Bandgar T, Menon P, Shah NS (2011) Tumor-induced osteomalacia: a single center experience. Endocr Pract 17:177–184CrossRefPubMed Jagtap VS, Sarathi V, Lila AR, Malhotra G, Sankhe SS, Bandgar T, Menon P, Shah NS (2011) Tumor-induced osteomalacia: a single center experience. Endocr Pract 17:177–184CrossRefPubMed
21.
go back to reference Roarke MC, Nguyen BD (2007) PET/CT localization of phosphaturic mesenchymal neoplasm causing tumor-induced osteomalacia. Clin Nucl Med 32:300–301CrossRefPubMed Roarke MC, Nguyen BD (2007) PET/CT localization of phosphaturic mesenchymal neoplasm causing tumor-induced osteomalacia. Clin Nucl Med 32:300–301CrossRefPubMed
22.
go back to reference Malhotra G, Agrawal A, Jambhekar NA, Sarathi V, Jagtap V, Agarwal MG, Kulkarni M, Asopa RV, Shah NS (2010) Interesting image. The search for primary tumor in a patient with oncogenic osteomalacia: F-18 FDG PET resolves the conundrum. Clin Nucl Med 35:896–898CrossRefPubMed Malhotra G, Agrawal A, Jambhekar NA, Sarathi V, Jagtap V, Agarwal MG, Kulkarni M, Asopa RV, Shah NS (2010) Interesting image. The search for primary tumor in a patient with oncogenic osteomalacia: F-18 FDG PET resolves the conundrum. Clin Nucl Med 35:896–898CrossRefPubMed
23.
go back to reference Chua SC, O’Connor SR, Wong WL, Ganatra RH (2008) Case report: solitary plasmacytoma of bone with oncogenic osteomalacia: recurrence of tumour confirmed by PET/CT. A case report with a review of the radiological literature. Br J Radiol 81:e110–e114CrossRefPubMed Chua SC, O’Connor SR, Wong WL, Ganatra RH (2008) Case report: solitary plasmacytoma of bone with oncogenic osteomalacia: recurrence of tumour confirmed by PET/CT. A case report with a review of the radiological literature. Br J Radiol 81:e110–e114CrossRefPubMed
24.
go back to reference Clifton-Bligh RJ, Hofman MS, Duncan E, Sim Ie W, Darnell D, Clarkson A, Wong T, Walsh JP, Gill AJ, Ebeling PR, Hicks RJ (2013) Improving diagnosis of tumor-induced osteomalacia with gallium-68 DOTATATE PET/CT. J Clin Endocrinol Metab 98:687–694CrossRefPubMed Clifton-Bligh RJ, Hofman MS, Duncan E, Sim Ie W, Darnell D, Clarkson A, Wong T, Walsh JP, Gill AJ, Ebeling PR, Hicks RJ (2013) Improving diagnosis of tumor-induced osteomalacia with gallium-68 DOTATATE PET/CT. J Clin Endocrinol Metab 98:687–694CrossRefPubMed
25.
go back to reference Seufert J, Ebert K, Muller J, Eulert J, Hendrich C, Werner E, Schuuze N, Schulz G, Kenn W, Richtmann H, Palitzsch KD, Jakob F (2001) Octreotide therapy for tumor-induced osteomalacia. N Engl J Med 345:1883–1888CrossRefPubMed Seufert J, Ebert K, Muller J, Eulert J, Hendrich C, Werner E, Schuuze N, Schulz G, Kenn W, Richtmann H, Palitzsch KD, Jakob F (2001) Octreotide therapy for tumor-induced osteomalacia. N Engl J Med 345:1883–1888CrossRefPubMed
26.
go back to reference Cescato R, Schulz S, Waser B, Eltschinger V, Rivier JE, Wester HJ, Culler M, Ginj M, Liu Q, Schonbrunn A, Reubi JC (2006) Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. J Nucl Med 47:502–511PubMed Cescato R, Schulz S, Waser B, Eltschinger V, Rivier JE, Wester HJ, Culler M, Ginj M, Liu Q, Schonbrunn A, Reubi JC (2006) Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. J Nucl Med 47:502–511PubMed
27.
go back to reference Andreopoulou P, Dumitrescu CE, Kelly MH, Brillante BA, Cutler Peck CM, Wodajo FM, Chang R, Collins MT (2011) Selective venous catheterization for the localization of phosphaturic mesenchymal tumors. J Bone Miner Res 26:1295–1302CrossRefPubMed Andreopoulou P, Dumitrescu CE, Kelly MH, Brillante BA, Cutler Peck CM, Wodajo FM, Chang R, Collins MT (2011) Selective venous catheterization for the localization of phosphaturic mesenchymal tumors. J Bone Miner Res 26:1295–1302CrossRefPubMed
28.
go back to reference Breer S, Brunkhorst T, Beil FT, Peldschus K, Heiland M, Klutmann S, Barvencik F, Zustin J, Gratz KF, Amling M (2014) 68Ga DOTA-TATE PET/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT/CT. Bone 64:222–227CrossRefPubMed Breer S, Brunkhorst T, Beil FT, Peldschus K, Heiland M, Klutmann S, Barvencik F, Zustin J, Gratz KF, Amling M (2014) 68Ga DOTA-TATE PET/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT/CT. Bone 64:222–227CrossRefPubMed
29.
go back to reference Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, Maecke H (2007) Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 34:982–993CrossRefPubMed Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, Maecke H (2007) Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 34:982–993CrossRefPubMed
30.
go back to reference Naswa N, Sharma P, Kumar R, Malhotra A, Bal C (2013) Successful localization of residual culprit tumor in a case of tumor-induced osteomalacia using 68Ga-DOTANOC PET/CT. Clin Nucl Med 38:639–640CrossRefPubMed Naswa N, Sharma P, Kumar R, Malhotra A, Bal C (2013) Successful localization of residual culprit tumor in a case of tumor-induced osteomalacia using 68Ga-DOTANOC PET/CT. Clin Nucl Med 38:639–640CrossRefPubMed
31.
go back to reference von Falck C, Rodt T, Rosenthal H, Langer F, Goesling T, Knapp WH, Galanski M (2008) 68Ga-DOTANOC PET/CT for the detection of a mesenchymal tumor causing oncogenic osteomalacia. Eur J Nucl Med Mol Imaging 35:1034CrossRef von Falck C, Rodt T, Rosenthal H, Langer F, Goesling T, Knapp WH, Galanski M (2008) 68Ga-DOTANOC PET/CT for the detection of a mesenchymal tumor causing oncogenic osteomalacia. Eur J Nucl Med Mol Imaging 35:1034CrossRef
32.
go back to reference Shane E, Parisien M, Henderson JE, Dempster DW, Feldman F, Hardy MA, Tohme JF, Karaplis AC, Clemens TL (1997) Tumor-induced osteomalacia: clinical and basic studies. J Bone Miner Res 12:1502–1511CrossRefPubMed Shane E, Parisien M, Henderson JE, Dempster DW, Feldman F, Hardy MA, Tohme JF, Karaplis AC, Clemens TL (1997) Tumor-induced osteomalacia: clinical and basic studies. J Bone Miner Res 12:1502–1511CrossRefPubMed
34.
go back to reference Carpenter TO, Ellis BK, Insogna KL, Philbrick WM, Sterpka J, Shimkets R (2005) Fibroblast growth factor 7: an inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors. J Clin Endocrinol Metab 90:1012–1020CrossRefPubMed Carpenter TO, Ellis BK, Insogna KL, Philbrick WM, Sterpka J, Shimkets R (2005) Fibroblast growth factor 7: an inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors. J Clin Endocrinol Metab 90:1012–1020CrossRefPubMed
35.
go back to reference Habra MA, Jimenez C, Huang SC, Cote GJ, Murphy WA Jr, Gagel RF, Hoff AO (2008) Expression analysis of fibroblast growth factor-23, matrix extracellular phosphoglycoprotein, secreted frizzled-related protein-4, and fibroblast growth factor-7: identification of fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein as major factors involved in tumor-induced osteomalacia. Endocr Pract 14:1108–1114CrossRefPubMed Habra MA, Jimenez C, Huang SC, Cote GJ, Murphy WA Jr, Gagel RF, Hoff AO (2008) Expression analysis of fibroblast growth factor-23, matrix extracellular phosphoglycoprotein, secreted frizzled-related protein-4, and fibroblast growth factor-7: identification of fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein as major factors involved in tumor-induced osteomalacia. Endocr Pract 14:1108–1114CrossRefPubMed
36.
go back to reference Hesse E, Rosenthal H, Bastian L (2007) Radiofrequency ablation of a tumor causing oncogenic osteomalacia. N Engl J Med 357:422–424CrossRefPubMed Hesse E, Rosenthal H, Bastian L (2007) Radiofrequency ablation of a tumor causing oncogenic osteomalacia. N Engl J Med 357:422–424CrossRefPubMed
37.
go back to reference Jadhav S, Kasaliwal R, Shetty NS, Kulkarni S, Rathod K, Popat B, Kakade H, Bukan A, Khare S, Budyal S, Jagtap VS, Lila AR, Bandgar T, Shah NS (2014) Radiofrequency ablation, an effective modality of treatment in tumor-induced osteomalacia: a case series of three patients. J Clin Endocrinol Metab 99:3049–3054CrossRefPubMed Jadhav S, Kasaliwal R, Shetty NS, Kulkarni S, Rathod K, Popat B, Kakade H, Bukan A, Khare S, Budyal S, Jagtap VS, Lila AR, Bandgar T, Shah NS (2014) Radiofrequency ablation, an effective modality of treatment in tumor-induced osteomalacia: a case series of three patients. J Clin Endocrinol Metab 99:3049–3054CrossRefPubMed
38.
go back to reference Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F et al (2004) Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 28:1–30CrossRefPubMed Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F et al (2004) Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 28:1–30CrossRefPubMed
Metadata
Title
Reports of 17 Chinese patients with tumor-induced osteomalacia
Authors
Wei-Jia Yu
Jin-Wei He
Wen-Zhen Fu
Chun Wang
Zhen-Lin Zhang
Publication date
01-05-2017
Publisher
Springer Japan
Published in
Journal of Bone and Mineral Metabolism / Issue 3/2017
Print ISSN: 0914-8779
Electronic ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-016-0756-9

Other articles of this Issue 3/2017

Journal of Bone and Mineral Metabolism 3/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.